Insider Trading Summary for Enliven Therapeutics, Inc. (ELVN): Three Months

Recent Insider Trades

Last Transaction		Last Three Months
SEC Filing	Transaction	Insider	Sentiment	Company	Holdings Change	Buy Amount	Sell Amount	Buy Price Range	Sell Price Range
15-Apr-24 7:05 PM View:	11-Apr-24 Planned Option Sale ($1.19M)	Kintz Samuel President and CEO Director		Enliven Therapeutics, Inc. - ELVN	0% 1.26M	0	0	--	--	Show Txns Hide Txns

15-Apr-24 7:04 PM View:	11-Apr-24 Planned Option Sale ($346.15K)	Hohl Benjamin Chief Financial Officer		Enliven Therapeutics, Inc. - ELVN	0% --	0	0	--	--	Show Txns Hide Txns

15-Apr-24 7:06 PM View:	11-Apr-24 Planned Option Sale ($751.33K)	Lyssikatos Joseph P Chief Scientific Officer Director		Enliven Therapeutics, Inc. - ELVN	0% 1.12M	0	0	--	--	Show Txns Hide Txns

15-Apr-24 7:06 PM View:	11-Apr-24 Sale (Planned) ($65.01K)	Patel Anish Chief Operating Officer		Enliven Therapeutics, Inc. - ELVN	(4%) 411.25K to 394.03K	0	0	--	--	Show Txns Hide Txns

15-Apr-24 7:03 PM View:	15-Apr-24 Sale (Planned) ($25.38K)	Heyman Richard A. Director		Enliven Therapeutics, Inc. - ELVN	(5%) 213.9K to 203.13K	0	0	--	--	Show Txns Hide Txns

16-Feb-24 4:15 PM View:	14-Feb-24 Private Sale ($12.29M)	5am Partners Vi, LLC 10% Owner		Enliven Therapeutics, Inc. - ELVN	(26%) 5.16M to 3.84M	0	0	--	--	Show Txns Hide Txns

12-Apr-24 6:23 PM View:	11-Apr-24 Planned Option Sale ($1.28M)	Ballal Rahul D. Director		Enliven Therapeutics, Inc. - ELVN	0% 22.34K	0	0	--	--	Show Txns Hide Txns

15-Apr-24 7:02 PM View:	11-Apr-24 Planned Option Sale ($501.48K)	Collins Helen Louise Chief Medical Officer		Enliven Therapeutics, Inc. - ELVN	0% --	0	0	--	--	Show Txns Hide Txns

Buy:	0	--
Sell:	0	--